Train harder · Free ship $75+ · Gear up now
Login Register
tirzepatide attenuates mammary tumor progression in diet induced obese mice

tirzepatide attenuates mammary tumor progression in diet induced obese mice How an anti-obesity drug improves metabolism beyond weight loss Incretin triple agonist retatrutide (LY3437943)

SKU: 88486740453

4.7
USD29.13 USD57.13

Pay in 4 interest-free payments of $7.28 Learn more

Shipping Estimate
USA
  • USA
  • CAN

Ships within 48 hours · Estimated delivery Sep 14 - Sep 19

Description

Retatrutide (LY3437943) is an investigational drug developed by Eli Lilly

tirzepatide attenuates mammary tumor progression in diet induced obese mice How an anti-obesity drug improves metabolism beyond weight loss Incretin triple agonist retatrutide (LY3437943)

(Fu et al., 2020)

tirzepatide attenuates mammary tumor progression in diet induced obese mice How an anti-obesity drug improves metabolism beyond weight loss Incretin triple agonist retatrutide (LY3437943)

Variations in dietary patternsincluding energy restriction, protein sources, calcium intake, and micronutrient supplementationcan also result in significantly different effects on bone metabolism

tirzepatide attenuates mammary tumor progression in diet induced obese mice How an anti-obesity drug improves metabolism beyond weight loss Incretin triple agonist retatrutide (LY3437943)

Heart disease facts

tirzepatide attenuates mammary tumor progression in diet induced obese mice How an anti-obesity drug improves metabolism beyond weight loss Incretin triple agonist retatrutide (LY3437943)
Exchange/Return Notes
  • We offer a 30-day return/exchange service after receiving.
  • Final sale items are not eligible for returns or exchanges.
  • To process your return/exchange, please contact us at [email protected]
  • Please click here for more details>>> Return & Exchange Policy

You may also like

recommand products